Introduction
The development of preimplantation embryos in vivo is promoted by a coordinated program involving soluble factors from the oviducts and the uterus (Yeung et al., 1992) . Prostaglandin I 2 (PGI 2 or prostacyclin), one of the factors produced by the oviducts and the uterus via the cyclooxygenase-2 (COX-2) pathway, plays a crucial role in embryo development and implantation (Lim et al., 1999; Huang et al., 2003; Huang et al., 2004a; Huang et al., 2004b) . Compared with the development of in vivo embryos, the development of cultured embryos, such as IVF embryos, is retarded because cultured embryos were deprived of the protective environment of the oviduct (Hardy, 1997) . Our recent work showed that supplementing culture media with iloprost, a stable analog of PGI 2 , enhances mouse blastocyst hatching in vitro (Huang et al., 2003) . Furthermore, embryos preconditioned by iloprost show an enhanced potential of implantation and live births when transferred to gestational carriers (Huang et al., 2004b) . A source of PGI 2 , other than the oviducts and uterus, is preimplantation embryos. Blocking the production of endogenous PGI 2 by selective COX-2 inhibitors retards embryo hatching (Huang et al., 2004c) . Thus, PGI 2 is crucial for embryo development in vitro, and its stable analog effectively improves the hatching and implantation of cultured embryos. It remains unclear how PGI 2 and its analogs achieve these enhancements.
PGI 2 exerts its effects by binding to a G-protein-coupled PGI 2 receptor (IP) and/or peroxisome proliferator-activated receptor δ (PPARδ) (Namba et al., 1994; Forman et al., 1997) . The inhibition of platelet aggregation and the relaxation of smooth muscle cells by PGI 2 are mediated by IP receptors via the 3′-5′-cyclic adenosine monophosphate (cAMP)-dependent kinase pathway (Namba et al., 1994) . PPARδ has been implicated in cell protection by PGI 2 (Adderley and Fitzgerald, 1999; Tan et al., 2001; Hao et al., 2002) . IP-null mice have increased propensity for thrombosis (Cheng et al., 2002) ; PPARδ-null mice exhibit reproductive defects (Barak et al., 2002; Cheng et al., 2002) . In at Pennsylvania State University on February 21, 2013 http://humrep.oxfordjournals.org/ Downloaded from this study, we tested the hypothesis that PGI 2 analogues enhance the development and hatching of preimplantation embryos via the PPARδ pathway. We obtained PPARδ -/-and wild-type (WT) embryos at the 2-cell stage and compared blastocyst formation, embryo hatching and implantation.
Material and methods

Harvest and culture of mouse embryos
The research protocol was approved by the Animal Welfare Committee of the University of Texas Health Science Center-Houston. Unless specified otherwise, all chemicals were purchased from Sigma (St. Louis, MO, USA). C3H, 129S1/SvImJ and C57BL6/J mice were obtained from the Jackson laboratory (Bar Harbor, ME, USA); ICR mice from Harlan (Indianapolis, IN, USA); PPARδ -/-mice from Dr R. Evans (the Salk Institute, La Jolla, CA, USA). WT PPARδ mice were bred by mating 129S1/SvImJ and the offspring of C57BL6/J × 129S1/SvImJ. Mice were kept in a temperature-and humidity-controlled environment (0700 h light on, 1900 h light off) with free access to food and water. Mouse embryos were harvested and cultured as described previously (Huang et al., 2003) . Briefly, 3-week-old female mice were induced to super-ovulate with i.p. injection of pregnant mare's serum gonadotrophin (5 IU) followed by HCG (5 IU) 42-46 h later. After HCG injection, each female mouse was caged with one male mouse of proven fertility. Two-cell embryos were harvested 44-48 h later and cultured (17-20 per group) at 37°C under 5% CO 2 in four-well plates (Nalge Nunc International, Naperville, IL, USA) containing 600 μl media. Human tubal fluid (HTF) media (Sage Biopharma, Bedminster, NJ, USA) were used during the first 48 h; α minimum essential medium (MEM) (Irvine Scientific, Santa Ana, CA, USA), with Earle's Salts and 2 mM glutamine, was used during the second 48 h. After culture for 96 h, embryos were examined for the presence of zona pellucida. Those completely free of the zona pellucida were considered completely hatched. The rate of complete hatching was calculated by dividing the number of completely hatched embryos by the number of total embryos. Complete embryo hatching was used as an endpoint because it is the last developmental stage before implantation and correlates with implantation and viable pregnancy (Huang et al., 2003; Huang et al., 2004b) . Where indicated, control embryos received the same concentration of vehicle [dimethylsulphoxide (DMSO), 1:10 000].
RNA extraction, RT-PCR and restriction enzyme digestion analysis
Total RNA was extracted from 20 blastocysts using a commercial kit (RNeasy; Qiagen, Chatsworth, CA, USA) and used for RT-PCR. The primers were selected based on mouse PPARδ sequence from the gene bank (NM_011145). A BLAST analysis showed there was no published mouse sequence that shared homology with the sequence of the 334-bp amplicon. RT was carried out at 42°C for 30 min using a primer (5′ TTCTAGAGCCCGCAGAATGG 3′) based on the nucleotide sequence from exon 6. The upstream (5′ GCCAAGAACATC-CCCAACTTC 3′) and downstream (5′ CCTGGATGGCTTCTAC CTGG 3′) primers were based on sequences from exons 5 and 6, respectively. The PCR consisted of 45 cycles of 94°C for 15 sec, 60°C for 1 min and 72°C for 1 min, and concluded with a 7-min extension at 72°C. PCRs were electrophoresed on an agarose gel. The amplicon was excised, eluted with QIAEX II Gel Extraction Kit (Qiagen) and digested by the restriction enzyme SST1 (Invitrogen, Carlsbad, CA, USA). The PCR products and the digested DNA (expected to yield two fragments, 95 and 239 bp) were separated by a 3% agarose gel and visualized with UV light.
Western blot analysis
Western blot analysis was performed as described previously (Huang et al., 2004c) , using an affinity purified, polyclonal antibody (Abcam Inc, Cambridge, MA, USA) against a mouse PPARδ peptide (MEQPQEETPEAREE). The cell lysate of blastocysts was prepared as follows. Twenty-five mouse blastocysts in 2 μl of media were transferred to 1.5-ml Eppendorf tubes containing 30 μl of lysis buffer (150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM sodium orthovanadate, 1mM EGTA and 1 mM sodium fluoride) and protease inhibitors [1 mM 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride, 0.8 μM aprotinin, 50 μM betastatin, 15 μM E-64, 20 μM leupeptin hemisulfate and 10 μM pepstatin A; CalbiochemNovabiochem Corp, San Diego, CA, USA]. The mixture was vortexed for 5 s, centrifuged for 10 s and stirred on ice for another 30 min, followed by two 1-s bursts of sonication (Branson Co, Danbury, CT, USA). After mixing with 4× protein loading dye, the supernatant was used for western blot analysis. The lysate was electrophoresed on a 12% gradient acrylamide gel and transferred to a nitrocellulose membrane (Schleicher & Schuell, Inc, Keene, NH, USA). The PPARδ protein bound by the antibody was visualized using enhanced chemifluorescence (GE Healthcare Bio-Sciences Corp, Piscataway, NJ, USA), whose signals were detected by a STORM 860 laser scanner (GE Healthcare Bio-Sciences Corp). Total cell lysate from mouse testes was used as a positive control.
Immunohistochemistry
The immunohistochemistry was performed as described previously (Huang et al., 2004c) . In brief, embryos were fixed in ice-cold phosphate-buffered saline (PBS) containing 4% buffered paraformaldehyde for 30 min. After permeabilization with 1% triton X-100 in PBS for 20 min, the embryos were incubated at 37°C with anti-PPARδ antibody (32 μg/ml) in PBS containing 5% milk for 30 min. The embryos were then incubated at 37°C in goat anti-rabbit immunoglobulin (Ig) G antibody conjugated with fluorescein isothiocyanate (FITC) (2.5 μg/ml, Invitrogen) for 30 min. Between incubations, embryos underwent four 5-min washes in PBS. After a final 5-min incubation in Hoechst 33258 (30 μg/ml) at room temperature, the embryos were mounted and examined under FITC and UV filters. Unfertilized eggs and embryos from various developmental stages (from one-cell embryos to blastocyst-stage embryos) were examined.
5-Bromo-2¢-deoxy-uridine uptake
The proliferation of embryonic cells was determined based on their abilities to incorporate 5-Bromo-2′-deoxy-uridine (BrdU). The assay was performed using BrdU Labeling and Detection Kit I (Roche Applied Science, Indianapolis, IN, USA) according to manufacturer's protocols with modifications. In brief, embryos were incubated in 100 μl pre-equilibrated HTF media containing 10 μM BrdU for 6 min at 37°C under 5% CO 2 , fixed in ice-cold glycine (50 mM) in 70% ethanol (pH 2.0) at -20°C for 30 min and incubated at 37°C for 30 min with diluted anti-BrdU mouse monoclonal antibody (1:2) buffer containing 1% bovine serum albumin (BSA). Embryos were washed in 200 μl PBS containing 1% BSA and incubated at 37°C for 30 min with diluted FITC-conjugated anti-rabbit IgG antibody (1:4) in PBS containing 1% BSA. After washing, embryos were treated with Hoechst 33258 (30 μg/ml) for 5 min at 25°C and mounted in 0.1 M Tris-HCl (pH 8.5) containing 16.6% elvanol 50-42 (DuPont, Wilmington, DE, USA) and 2.5% 1,4-diazabicyclo-(2.2.2)-octane. Cells that incorporated BrdU were identified under a FITC filter (AxioPlan 2, Zeiss, Oberkochen, Germany). Total cell number was determined based on Hoechst 33258 nuclear staining under a UV filter.
Embryo transfer and determination of implantation rate
Embryo transfer was performed as described previously (Huang et al., 2004b) . Briefly, embryos were transferred to gestational carriers (ICR female mice) on day 2.5 of pseudopregnancy under a dissecting microscope (Olympus SZ-PT, Shinjuku-ku, Tokyo, Japan). After anaesthesia, each uterine horn was accessed via a 1.5-cm flank incision. With the proximal oviduct held by a pair of forceps, an opening was created at the distal end of the uterine horn on the anti-mesenteric side with a 30-gauge needle. The opening permitted the entry of the transfer pipette which had an inner diameter of 135 μm (MidAtlantic Diagnostics, Inc, Mount Laurel, NJ, USA). Up to seven embryos in 1.5-μl transfer medium (MEM with 25 mM HEPES and 1% BSA) were transferred to each horn. After each transfer, the contents of the pipette were examined under a stereomicroscope to identify retained embryos. To avoid the mixing of embryos as a result of embryo crossover (Dr Andreas Zimmer, University of Bonn, Germany, MGI-List, the Jackson Laboratory), each gestational carrier received only one kind of embryo. To maintain consistent transfer techniques, the embryo transfer was performed following the same protocol and by one individual (J.-C.H.). Seventy-two hours after embryo transfer, the rates of implantation were determined based on a previously described method with modifications (Paria et al., 1993) . Briefly, 3 min before euthanasia, 0.1 ml of Chicago blue (1%) was injected via the tail vein of the gestational carrier. After the carrier was sacrificed, the uterine horns were opened and the gestation sacs counted. The implantation rate was expressed as percentages of gestation sacs over total embryos transferred. Ninety-seven WT and fifty-four PPARδ -/-embryos were transferred to seven and four gestational carriers, respectively.
Statistical analysis
Prism® Version 3.0 (GraphPad Software Inc, San Diego, CA, USA), with the Hill slope set at 1.0, was used to estimate the ED 50 of L-165041. Chi-square and Student's t-tests were used where appropriate (InStat® Version 3.05, GraphPad Software Inc). A P < 0.05 was considered statistically significant.
RESULTS
Essential role of PPARd in preimplantation embryo development in vitro
Blastocyst-stage embryos expressed PPARδ mRNA and protein as determined by RT-PCR and western blots, respectively (Figure 1a and (Figure 2) . Iloprost (0.1 μM) increased the number of completely hatched embryos to 50% (37/74) in WT but had no effect on PPARδ -/-embryos (3/144). L-165041, a specific PPARδ ligand (Berger et al., 1999) , increased the proportion of completely hatched WT embryos to 58%, as compared with 30% in untreated WT embryos. Neither iloprost nor L-165041 affected the hatching of PPARδ -/-embryos. Combined iloprost and L-165041 treatment increased hatched WT embryos to 62%, an enhancement which is not significantly greater than that of either ligand alone. These results suggest that iloprost and L-165041 act via PPARδ. Experiments were then performed to determine the role of PPARδ in embryo development. Two-cell embryos from WT and PPARδ -/-mice were cultured in media without PPARδ ligands for 96 h. At 48, 72 and 96 h, blastocyst-, morula-and earlier-stage embryos (designated as < morula) were counted. PPARδ -/-embryos developed significantly more slowly than WT embryos at each time point (Table I) . At 96 h, 29% of the PPARδ -/-embryos remained at < morula stages and 28% were hatching or hatched, whereas all WT embryos had reached the blastocyst stage and 85% underwent hatching or had completely hatched. It is worth mentioning that preliminary experiments showed that extending the culture to 120 h did not change the percentages of completely hatched embryos in either group (not shown). Taken together, these data indicate that PPARδ is fundamental to embryo development and hatching in vitro. To test the hypothesis that the impaired hatching of PPARδ -/-embryos is a result of decreased cell proliferation, we compared the BrdU uptake by WT and PPARδ -/-embryos. The number of BrdU-positive cells was greatly reduced in PPARδ -/-embryos ( Figure 3a) . Cell numbers per embryo were also markedly reduced in PPARδ -/-embryos ( Figure 3b ). 
Stimulation of embryo hatching by PPARd ligands
Iloprost and L-165041 increased WT embryo hatching to a similar extent (Figure 2 ). Their stimulatory effects were abrogated by PPARδ deletion (Figure 2 ). L-165041 increased the percentage of hatched embryos in a concentration-dependent manner with an ED50 value of 21 nM ( Figure 4a ). Neither Wy14,643, a PPARα ligand, nor ciglitazone, a PPARγ agonist, stimulated embryo hatching (Figure 4b ). L-165041 was effective in stimulating embryo hatching when it was added to embryos at 2-cell, 8-cell or morula stage (Figure 4c ). Once a majority of embryos reached the blastocyst stage, the addition of L-165041 to the cultured medium was no longer effective in stimulating hatching (Figure 4c ). L-165041 (10 μM) increased the percentages of BrdU-positive cells over the untreated control (Figure 4d ). Taken together, these results indicate that exogenous PPARδ ligands such as L-165041 and iloprost accelerate hatching by stimulating the cell proliferation in embryos.
Regulation of embryo implantation by PPARd
To determine the extent to which PPARδ is involved in implantation, 2-cell embryos obtained from WT and PPARδ -/-mice were cultured for 48 h, enumerated and transferred to -/-embryos had significantly lower rates of complete hatching and did not respond to either iloprost or L-165041. The numbers in the parentheses denote the number of completely hatched embryos versus total embryos. *P < 0.05 and **P < 0.01 (versus control embryos, chi-square test). (7) 15 (54) Figure 3 . Peroxisome proliferator-activated receptor δ (PPARδ) deletion decreases embryonic cell proliferation. Wild-type (WT) and PPARδ -/-embryos were cultured for 72 h beginning at the 2-cell stage. 5-Bromo-2′-Deoxy-Uridine (BrdU) uptake and cell numbers were determined as described in the Materials and methods. WT embryos had more cell proliferation as suggested by significantly more BrDu-positive cells per embryo (a). As a result, WT embryos have more cells per embryo (b). The figure depicts the result of one representative experiment using 22 WT and 20 PPARδ -/-embryos; same results were observed in two other experiments using similar number of embryos. *P < 0.01. receptive uteri of gestational carriers. Gestation sacs were counted 72 h later. Numbers of early and late blastocysts developed from 2-cell-stage PPARδ -/-embryos were significantly lower than those developed from WT embryos ( Figure  5a ). The implantation rate for PPARδ -/-embryos was also significantly lower than that for WT embryos (28 versus 44%, P < 0.05) (Figure 5b ). We next determined the extent to which pretreatment of 2-cell embryos with L-165041 influences implantation rate. Two-cell embryos from WT mice were treated with L-165041 for 48 h. Embryos were enumerated and transferred to gestational carriers. Implantation rate was evaluated 72 h later. Although L-165041 did not significantly enhance blastocyst formation (Figure 5c ), it significantly increased the implantation rate (64 versus 41%, P < 0.05) (Figure 5d ). These results indicate that embryo PPARδ plays an important role in implantation. Exogenous PPARδ ligands promote implantation without altering blastocyst formation.
Discussion
Our study suggests that embryo development and hatching requires PPARδ. Two-cell embryos from PPARδ -/-mice are capable of developing into blastocysts, but the rate of blastocyst formation lags behind that of WT embryos. PPARδ is especially fundamental to blastocyst hatching. Compared with WT embryos, a significant number of two-cell PPARδ -/-embryos failed to hatch after 96 h in culture. It is worth mentioning that extending the culture duration to 120 h did not change the outcome as the majority of the blastocysts collapsed during this period. It has been proposed that embryo hatching is mediated by two major factors: (i) a crucial cell number increase in embryos (Montag et al., 2000) , which results in thinning of zona pellucida, and (ii) the digestion of zona by proteolytic enzymes (Sawada et al., 1990) . Our results reveal that PPARδ mediates the proliferation of embryonic cells and thereby increases embryonic cell mass. Compared with WT embryos, PPARδ -/-embryos exhibit very low BrdU incorporation. The cell numbers of PPARδ -/-embryos were only about 30% of those of WT embryos after 72 h in culture.
PPARδ is a nuclear receptor which binds a number of endogenous and synthetic ligands (Forman et al., 1997) . Our previous study suggests that COX-2-derived PGI 2 in embryos may be an endogenous PPARδ ligand (Huang et al., 2004c) . Ligandactivated PPARδ forms a heterodimer with retinoid X receptor which binds PPAR response elements and activates gene transcription (Kliewer et al., 1994) . A number of PPARδ-mediated genes have been reported, and two of these genes, 14-3-3ε and phosphoinositide-dependent kinase-1 (PDK-1), are involved in protecting cells from apoptosis (Di-Poi et al., 2002; Liou et al., 2006) . However, the mechanism by which PPARδ promotes embryo cell proliferation is unknown. It was reported that overexpression of PPARδ in the vascular smooth muscle cells increases post-confluent cell proliferation by increasing cyclin A and cyclin-dependent kinase 2 as well as decreasing p57kip2 (Zhang et al., 2002) . It is possible that PPARδ-mediated 14-3-3 up-regulation is involved in cell proliferation, because 14-3-3 proteins are considered to be scaffolds for a large number of proteins, including signalling molecules and receptors (Fu et al., 2000; Tzivion and Avruch, 2002) . Work is in progress to address this possibility. PPARδ may also play an important role in protecting embryo cells from apoptosis via 14-3-3ε (Liou et al., 2006) and PDK-1 (Di-Poi et al., 2002) . It was reported that the inner Figure 5 . Peroxisome proliferator-activated receptor δ (PPARδ) activation enhances the implantation of cultured embryos. Ninety-seven PPARδ +/+ and 54 PPARδ -/-embryos at 2-cell stage were cultured for 48 h. The embryos were transferred to gestational carriers after their developmental stages were recorded. The numbers of gestation sacs were determined 72 h later. Significantly, fewer PPARδ -/-embryos developed to blastocysts (a). When transferred to carriers, PPARδ -/-embryos had significantly lower implantation rates (b). Fifty-six and 42 PPARδ +/+ embryos received dimethylsulphoxide (DMSO) and l165041, respectively, for 48 h beginning at two-cell stage. After stages of development were recorded, the embryos were transferred to gestational carriers. The numbers of gestation sacs were determined 72 h later. The extent of embryo development was similar in both groups at the time of embryo transfer (c). However, L-165041-treated embryos had significantly higher implantation rates (d). Numbers in the parentheses refer to the number of gestation sacs and the number of embryos transferred. *P < 0.05; **P < 0.01.
cell mass (ICM) of blastocytes in culture is vulnerable to oxidative apoptosis (Brison and Schultz, 1997; Schratt et al., 2004) . PGI 2 -activated PPARδ may protect ICM from apoptosis by up-regulating 14-3-3ε, which sequesters Bad phosphorylated via the PDK-1 and Akt pathway (Zha et al., 1996; Datta et al., 1997) . The anti-apoptotic function of PPARδ may contribute to increased cell numbers in blastocysts and enhanced hatching. It has been reported that COX-2-derived PGI 2 in the uterus is involved in embryo implantation, and PPARδ has been implicated for the action of PGI 2 (Lim et al., 1999) . The role of the embryo PPARδ in implantation has not been reported.
Results from the present study provide direct evidence for a crucial role of embryo PPARδ in implantation. To mimic IVF procedures, we cultured WT and PPARδ -/-2-cell embryos in vitro for 48 h. Embryos at various stages of development were counted and transferred to receptive gestational carriers. Gestation sacs in the uterus were counted 72 h later. The number of gestation sacs from PPARδ -/-embryos was significantly less than that from WT embryos. Reduced implantation of PPARδ -/-embryos is correlated with the retarded embryo development and blastocyst formation of PPARδ -/-embryos. These results underscore the importance of PPARδ-mediated, enhanced cell proliferation in promoting the growth, maturation (hatching) and implantation of preimplantation embryos.
A major goal of our studies is to improve IVF. We have previously reported that iloprost, a stable PGI 2 analogue, enhances embryo implantation and the potential of live birth (Huang et al., 2004b) . In the present study, we confirmed the previous data and shed light on the mechanism by which exogenous iloprost enhances embryo hatching and implantation. Our results show that PPARδ is the target of PGI 2 in the preimplantation embryos. Enhanced blastocyst hatching by iloprost was completely abrogated in PPARδ -/-embryos. A synthetic PPARδ ligand, L-165041, exerted an effect similar to that of iloprost, but a combination of iloprost with L-165041 did not have additional effects. These results further suggest that endogenous PGI 2 production in cultured embryos is limited and that exogenous PGI 2 analogue or synthetic PPARδ ligand can further activate PPARδ. PPARδ activation by synthetic ligand or PGI 2 analogue (iloprost) promotes further cell proliferation resulting in a higher hatching rate. It is worth noting that the effect of L-165041 is not limited to 2-cell-stage embryos. L-165041 was quite effective in enhancing embryo hatching even in morulastage embryos. However, L-165041 did not appear to be effective in blastocyst-stage embryos. The afore-mentioned result is probably because some blastocysts had advanced development and were ready to hatch. This observation is of practical importance with respect to the timing of supplementing media with iloprost or PPARδ ligands. Naturally, the application of PPARδ ligands in human IVF requires a thorough investigation of its safety profiles.
L-165041 appears to enhance embryo implantation by a mechanism independent of its effect on blastocyst formation, because the developmental stages of control and experimental embryos at the time of embryos transfer were similar, yet transferred experimental embryos resulted in more gestation sacs. The molecular basis for the delayed action is unclear. We speculate that L-165041 induces a sustained signalling activation via PPARδ to enhance implantation. These sustained effects may include (i) continued enhancement of embryo development after embryos were transferred and/or (ii) enhanced ability of embryos to communicate with the maternal interface (i.e. cross-talk between the transcriptional signallings of uterine and embryo PPARδ, as the embryos float in the uterine cavity and interact with the endometrium before implantation). The coordination between embryo development and endometrial decidualization ensures a successful implantation. Elucidation of the molecular mechanism(s) will have major impacts on our understanding of embryo implantation and the potential to improve IVF success.
In summary, preimplantation embryos express PPARδ, which plays an essential role in embryo development, blastocyst formation, embryo hatching and implantation. Activation of embryo PPARδ is a novel therapeutic strategy to improve the outcome of IVF.
